Literature DB >> 22096454

Hypertension in Cardiovascular and Kidney Disease.

Joshua Botdorf1, Kunal Chaudhary, Adam Whaley-Connell.   

Abstract

The relationship between hypertension and chronic kidney disease (CKD) is bidirectional in nature and, generally, management strategies for cardiovascular risk reduction also attenuate progression of CKD. Prevalent hypertension increases with diminishing kidney function, and the management strategy changes with level of kidney function. In this review, we will examine the evidence for management of hypertension, as a modifiable risk factor for cardiovascular disease in CKD, and the impact of this management on progression of CKD.

Entities:  

Year:  2011        PMID: 22096454      PMCID: PMC3169371          DOI: 10.1159/000329927

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  56 in total

1.  Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.

Authors:  Philip Kam-Tao Li; Chi Bon Leung; Kai Ming Chow; Yuk Lun Cheng; Samuel Ka-Shun Fung; Siu Ka Mak; Anthony Wing-Chung Tang; Teresa Yuk-Hwa Wong; Chun Yu Yung; Jonathan Chee-Unn Yung; Alex Wai-Yin Yu; Cheuk Chun Szeto
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

Review 2.  The incidence and implications of aldosterone breakthrough.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Nat Clin Pract Nephrol       Date:  2007-09

3.  Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy.

Authors:  Jodi Heshka; Marcel Ruzicka; Swapnil Hiremath; Brendan B McCormick
Journal:  J Am Soc Hypertens       Date:  2010 Nov-Dec

4.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors:  Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

5.  The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.

Authors:  H Buter; M H Hemmelder; G Navis; P E de Jong; D de Zeeuw
Journal:  Nephrol Dial Transplant       Date:  1998-07       Impact factor: 5.992

Review 6.  Association between obesity and kidney disease: a systematic review and meta-analysis.

Authors:  Y Wang; X Chen; Y Song; B Caballero; L J Cheskin
Journal:  Kidney Int       Date:  2007-10-10       Impact factor: 10.612

Review 7.  Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.

Authors:  Barry L Carter; Michael E Ernst; Jerome D Cohen
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

8.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

9.  Early predictors of 15-year end-stage renal disease in hypertensive patients.

Authors:  H M Perry; J P Miller; J R Fornoff; J D Baty; M P Sambhi; G Rutan; D W Moskowitz; S E Carmody
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

10.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group.

Authors:  N B Shulman; C E Ford; W D Hall; M D Blaufox; D Simon; H G Langford; K A Schneider
Journal:  Hypertension       Date:  1989-05       Impact factor: 10.190

View more
  15 in total

Review 1.  Chronic kidney disease in the pathogenesis of acute ischemic stroke.

Authors:  Bharath Chelluboina; Raghu Vemuganti
Journal:  J Cereb Blood Flow Metab       Date:  2019-08-01       Impact factor: 6.200

2.  Spleno-renal artery transposition in a solitary functioning kidney for treatment-resistant hypertension and acute kidney injury.

Authors:  Subash Somalanka; Fiona E Harris; Eric Chemla; Rebecca Jo Suckling; Pauline A Swift
Journal:  BMJ Case Rep       Date:  2017-08-16

3.  Altered microRNA regulation of short chain fatty acid receptors in the hypertensive kidney is normalized with hydrogen sulfide supplementation.

Authors:  Gregory J Weber; Jaleyea Foster; Sathnur B Pushpakumar; Utpal Sen
Journal:  Pharmacol Res       Date:  2018-06-15       Impact factor: 7.658

4.  Hypertension increases with aging and obesity in chimpanzees (Pan troglodytes).

Authors:  John J Ely; Tony Zavaskis; Michael L Lammey
Journal:  Zoo Biol       Date:  2012-09-11       Impact factor: 1.421

5.  Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.

Authors:  Adam Whaley-Connell; Javad Habibi; Nathan Rehmer; Sivakumar Ardhanari; Melvin R Hayden; Lakshmi Pulakat; Caroline Krueger; Carlos M Ferrario; Vincent G DeMarco; James R Sowers
Journal:  Metabolism       Date:  2013-01-24       Impact factor: 8.694

6.  CXCL16: a chemokine-causing chronic kidney disease.

Authors:  Allison E Norlander; Mohamed A Saleh; Meena S Madhur
Journal:  Hypertension       Date:  2013-09-23       Impact factor: 10.190

7.  Heterogeneity of treatment effect in SPRINT by age and baseline comorbidities: The greatest impact of intensive blood pressure treatment is observed among younger patients without CKD or CVD and in older patients with CKD or CVD.

Authors:  Ara H Rostomian; Maxine C Tang; Jonathan Soverow; Daniel R Sanchez
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-16       Impact factor: 3.738

8.  Chemical renal artery denervation with appropriate phenol in spontaneously hypertensive rats.

Authors:  Ming Wang; Wen-Zheng Han; Min Zhang; Wei-Yi Fang; Xin-Rong Zhai; Shao-Feng Guan; Xin-Kai Qu
Journal:  J Geriatr Cardiol       Date:  2018-11       Impact factor: 3.327

9.  Myocardial Stunning with Hemodialysis: Clinical Challenges of the Cardiorenal Patient.

Authors:  Mozow Y Zuidema; Kevin C Dellsperger
Journal:  Cardiorenal Med       Date:  2012-03-30       Impact factor: 2.041

10.  Hypertension Management in Diabetic Kidney Disease.

Authors:  Vikram Patney; Adam Whaley-Connell; George Bakris
Journal:  Diabetes Spectr       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.